 The adjuvant recombinant SOSTA vaccine demonstrated greater than 90% efficacy against herpes SOSTA in two pivotal studies involving adults aged greater than or equal to 50 and greater than or equal to 70 years, with efficacy remaining high irrespective of the number of selected medical conditions reported by a participant. No safety concerns were identified based on the type or number of medical conditions present at enrollment. This article was authored by Lydia East Vogels, Thomas C. Heineman, Robert W. Johnson, and others.